Published in Cardiovasc Res on January 15, 2010
Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med (2016) 2.85
Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res (2011) 2.37
Inherited calcium channelopathies in the pathophysiology of arrhythmias. Nat Rev Cardiol (2012) 1.44
Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. Circ Res (2010) 1.41
The ryanodine receptor store-sensing gate controls Ca2+ waves and Ca2+-triggered arrhythmias. Nat Med (2014) 1.29
Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res (2013) 1.22
Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol (2011) 1.19
Abnormal termination of Ca2+ release is a common defect of RyR2 mutations associated with cardiomyopathies. Circ Res (2012) 1.11
Calsequestrin 2 and arrhythmias. Am J Physiol Heart Circ Physiol (2011) 1.08
Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease. Circ Res (2014) 1.06
A novel ryanodine receptor mutation linked to sudden death increases sensitivity to cytosolic calcium. Circ Res (2011) 0.96
A novel computational model of mouse myocyte electrophysiology to assess the synergy between Na+ loading and CaMKII. J Physiol (2014) 0.94
Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice. Circ Res (2013) 0.92
Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients. Circ Res (2013) 0.91
Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. Circ Res (2015) 0.91
Cardiac disease and arrhythmogenesis: Mechanistic insights from mouse models. Int J Cardiol Heart Vasc (2016) 0.90
JTV519 (K201) reduces sarcoplasmic reticulum Ca²⁺ leak and improves diastolic function in vitro in murine and human non-failing myocardium. Br J Pharmacol (2012) 0.89
Targeting ryanodine receptors for anti-arrhythmic therapy. Acta Pharmacol Sin (2011) 0.88
Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies. Appl Clin Genet (2013) 0.87
Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia. Pediatr Cardiol (2012) 0.85
TRPC3 contributes to regulation of cardiac contractility and arrhythmogenesis by dynamic interaction with NCX1. Cardiovasc Res (2015) 0.83
The effect of K201 on isolated working rabbit heart mechanical function during pharmacologically induced Ca2+ overload. Br J Pharmacol (2012) 0.81
β-Adrenergic stimulation increases the intra-sarcoplasmic reticulum Ca2+ threshold for Ca2+ wave generation. J Physiol (2012) 0.80
Modulation of the cardiac sodium/bicarbonate cotransporter by the renin angiotensin aldosterone system: pathophysiological consequences. Front Physiol (2014) 0.79
Stochastic initiation and termination of calcium-mediated triggered activity in cardiac myocytes. Proc Natl Acad Sci U S A (2017) 0.78
New antiarrhythmic targets to control intracellular calcium handling. Neth Heart J (2014) 0.78
p21-Activated kinase1 (Pak1) is a negative regulator of NADPH-oxidase 2 in ventricular myocytes. J Mol Cell Cardiol (2013) 0.77
Regulation of the cardiac sodium/bicarbonate cotransporter by angiotensin II: potential Contribution to structural, ionic and electrophysiological myocardial remodelling. Curr Cardiol Rev (2013) 0.76
R4496C RyR2 mutation impairs atrial and ventricular contractility. J Gen Physiol (2015) 0.75
β-adrenergic stimulation increases the intra-SR Ca termination threshold for spontaneous Ca waves in cardiac myocytes. Channels (Austin) (2013) 0.75
Calcium polymorphic ventricular tachycardia: a new name for CPVT? Cardiovasc Res (2010) 0.75
Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis. J Obes (2016) 0.75
CPVT-associated cardiac ryanodine receptor mutation G357S with reduced penetrance impairs Ca2+ release termination and diminishes protein expression. PLoS One (2017) 0.75
Therapeutic Strategies Targeting Inherited Cardiomyopathies. Curr Heart Fail Rep (2017) 0.75
Universal definition of myocardial infarction. Circulation (2007) 11.69
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell (2004) 7.45
Risk stratification in the long-QT syndrome. N Engl J Med (2003) 7.25
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation (2002) 5.94
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell (2003) 4.68
Pluripotency of spermatogonial stem cells from adult mouse testis. Nature (2006) 4.29
The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res (2003) 4.13
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res (2005) 3.75
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA (2005) 3.51
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J (2004) 3.45
Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res (2005) 3.44
Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest (2006) 3.33
Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA (2004) 3.24
Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res (2007) 3.20
Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol (2011) 3.13
PLC zeta: a sperm-specific trigger of Ca(2+) oscillations in eggs and embryo development. Development (2002) 3.13
Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation (2008) 3.11
Natural history of Brugada syndrome: insights for risk stratification and management. Circulation (2002) 3.10
Reduced synchrony of Ca2+ release with loss of T-tubules-a comparison to Ca2+ release in human failing cardiomyocytes. Cardiovasc Res (2004) 3.10
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proc Natl Acad Sci U S A (2004) 2.88
High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation (2008) 2.83
Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res (2006) 2.81
Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell (2009) 2.78
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Moderate hypothermia for severe cardiogenic shock (COOL Shock Study I & II). Resuscitation (2012) 2.70
The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A (2009) 2.66
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ Res (2005) 2.50
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol (2008) 2.49
Calcium cycling in congestive heart failure. J Mol Cell Cardiol (2002) 2.46
Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res (2003) 2.44
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res (2010) 2.38
Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol (2012) 2.37
Venice Chart international consensus document on atrial fibrillation ablation. J Cardiovasc Electrophysiol (2007) 2.25
A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc Electrophysiol (2003) 2.24
Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol (2003) 2.22
Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther (2006) 2.21
Reduced heterogeneous expression of Cx43 results in decreased Nav1.5 expression and reduced sodium current that accounts for arrhythmia vulnerability in conditional Cx43 knockout mice. Heart Rhythm (2011) 2.21
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20
Differential cardiac remodeling in preload versus afterload. Circulation (2010) 2.20
Cost-effectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J (2006) 2.15
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol (2011) 2.15
Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12
Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation (2005) 2.10